| Transporter |
Gene (locus) |
Substrate specificity
|
Transport inhibitors |
GDM effect in human fetal endothelium |
GDM effect in CNS |
| hENT1 |
SLC29A1
(6p21.2-p21.1) |
Purine and pyrimidine
nucleosides |
NBTI (<1 μM)
dipyridamole, dilazep |
Decreased expression and activity in HUVEC and hPMEC* |
Decreased expression and activity in mouse fetal astrocytes** |
| hENT2 |
SLC29A2
(11q13) |
Purine and pyrimidine
nucleosides |
NBTI (>1 μM) hypoxanthine |
Unaltered expression and activity in HUVEC
Decreased expression and activity in hPMEC* |
Decreased expression and activity in mouse fetal astrocytes** |
| hENT3 |
SLC29A3
(10q22.2) |
Purine and pyrimidine
nucleosides, nucleobases,
monoamines |
NBTI (>1 μM) dipyridamole |
nr |
nr |
| hENT4 |
SLC29A4
(7p22) |
Purine and serotonin |
NBTI (>10 μM)
uridine |
nr |
nr |
| hENT: Human Equilibrative Nucleoside Transporter isoform; SLC: Solute Like Carriers; NBTI: Nitrobenzylthioinosine; HUVEC: Human Umbilical Vein Endothelial Cells; hPMEC: Human Placental Microvascular Endothelial Cells; nr: not reported. From data in references [42,143-146]. *C Salomón, F Westermeier, L Sobrevia, unpublished. *P Arroyo, L Sobrevia, unpublished. |
